• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session

    5/6/24 7:32:06 AM ET
    $ADCT
    $BNTX
    $LAZR
    $MPW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADCT alert in real time by email

    U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Monday.

    Shares of BioNTech SE (NASDAQ:BNTX) fell sharply in today's pre-market trading following weaker-than-expected first-quarter earnings.

    BioNTech posted quarterly GAAP loss of €1.31 per share, missing estimates of €0.97 per share. The company's sales came in at €187.600 million missing estimates of €427.500 million.

    BioNTech shares fell 4.4% to $88.65 in pre-market trading in pre-market trading.

    Here are some big stocks recording losses in today's pre-market trading session.

    • Medical Properties Trust, Inc (NYSE:MPW) shares declined 14.4% to $4.17 in pre-market trading after tenant Steward Health Care reportedly filed for bankruptcy protection.
    • Embotelladora Andina S.A.  (NYSE:AKO) fell 10.8% to $16.65 pre-market trading after gaining 4% on Friday.
    • Luminar Technologies, Inc. (NASDAQ:LAZR) shares declined 9.5% to $1.52 in pre-market trading after the company announced a workforce reduction.
    • MMTec, Inc. (NASDAQ:MTC) dipped 8% to $2.19 in pre-market trading after declining 4% on Friday.
    • Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares fell 7.6% to $5.70 in pre-market trading after gaining 5% on Friday.
    • ADC Therapeutics SA. (NYSE:ADCT) shares declined 6.3% to $4.59 in pre-market trading after the company posted weak quarterly sales.
    • Victoria’s Secret & Co (NYSE:VSCO) fell 5% to $16.67 pre-market trading. Morgan Stanley analyst Alexandra Steiger downgraded Victoria’s Secret from Equal-Weight to Underweight and lowered the price target from $19 to $15.

    Now Read This: Jim Cramer Says ‘You’re In Good Hands’ With This ‘Very Good’ Regional Bank, Likes General Motors

    Don't forget to check out our premarket coverage here

    Get the next $ADCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADCT
    $BNTX
    $LAZR
    $MPW

    CompanyDatePrice TargetRatingAnalyst
    Victorias Secret & Co.
    $VSCO
    3/2/2026$66.00 → $71.00Outperform
    Telsey Advisory Group
    BioNTech SE
    $BNTX
    2/2/2026$113.00Outperform → Market Perform
    Leerink Partners
    BioNTech SE
    $BNTX
    1/16/2026$142.00Neutral → Buy
    Goldman
    Victorias Secret & Co.
    $VSCO
    12/17/2025$66.00Market Perform → Outperform
    Telsey Advisory Group
    Victorias Secret & Co.
    $VSCO
    12/16/2025$45.00Underweight → Equal Weight
    Wells Fargo
    Victorias Secret & Co.
    $VSCO
    12/10/2025Neutral
    Guggenheim
    Victorias Secret & Co.
    $VSCO
    12/8/2025$52.00Underperform → Neutral
    BofA Securities
    Victorias Secret & Co.
    $VSCO
    12/8/2025$45.00 → $50.00Market Perform
    Telsey Advisory Group
    More analyst ratings

    $ADCT
    $BNTX
    $LAZR
    $MPW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tim Johnson Nominated to Join Amaero Board

    MCDONALD, Tenn., March 10, 2026 (GLOBE NEWSWIRE) -- Amaero Ltd (ASX:3DA) (OTC:AMROF) ("Amaero" or the "Company"), a leading U.S. domestic producer of high-value refractory and titanium alloy powders for additive and advanced manufacturing of components utilized by the defense, space, and aviation industries, is pleased to announce that Tim "TJ" Johnson has been nominated to join Amaero's Board as a Non-Executive Director, subject to satisfying the requisite regulatory requirements. Upon joining the Board as a Non-Executive Director, it is anticipated that he will assume the responsibilities of Chairman of the Audit and Risk Committee. Mr. Johnson is an experienced corporate board member

    3/10/26 8:00:00 AM ET
    $DLTR
    $DRVN
    $EAT
    Department/Specialty Retail Stores
    Consumer Discretionary
    Automotive Aftermarket
    Restaurants

    ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

    LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026Recent amendment to HealthCare Royalty financing agreement increases strategic flexibilityFourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028Company to host conference call today at 8:30 a.m. EDTLAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results f

    3/10/26 7:30:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

    BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb Full year 2025 revenues of €2.9 billion2, net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.314) (adjusted3 diluted loss per share of €0.48 ($0.554)) Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5Expect 202

    3/10/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADCT
    $BNTX
    $LAZR
    $MPW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on Victoria's Secret with a new price target

    Telsey Advisory Group reiterated coverage of Victoria's Secret with a rating of Outperform and set a new price target of $71.00 from $66.00 previously

    3/2/26 8:10:51 AM ET
    $VSCO
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    BioNTech downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded BioNTech from Outperform to Market Perform and set a new price target of $113.00

    2/2/26 6:48:45 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioNTech upgraded by Goldman with a new price target

    Goldman upgraded BioNTech from Neutral to Buy and set a new price target of $142.00

    1/16/26 8:19:35 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADCT
    $BNTX
    $LAZR
    $MPW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Jeggle Helmut Wolfgang

    3 - BioNTech SE (0001776985) (Issuer)

    3/18/26 5:39:22 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Poetting Sierk

    3 - BioNTech SE (0001776985) (Issuer)

    3/18/26 5:41:10 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Motschmann Michael

    3 - BioNTech SE (0001776985) (Issuer)

    3/18/26 5:43:08 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADCT
    $BNTX
    $LAZR
    $MPW
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-5) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:04:01 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-4) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:03:14 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (ORIG-1) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 04/23/2021. Application Category: BLA, Application Number: 761196, Application Classification:

    4/23/21 1:46:03 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    $BNTX
    $LAZR
    $MPW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ADCT
    $BNTX
    $LAZR
    $MPW
    SEC Filings

    View All

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lindstrom Richard L Md bought $69,600 worth of shares (10,000 units at $6.96), increasing direct ownership by 6% to 172,704 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    5/12/25 8:50:46 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Bbrc International Pte Ltd bought $3,431,620 worth of shares (212,500 units at $16.15) (SEC Form 4)

    4 - Victoria's Secret & Co. (0001856437) (Issuer)

    4/4/25 4:15:14 PM ET
    $VSCO
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    SEC Form EFFECT filed by ADC Therapeutics SA

    EFFECT - ADC Therapeutics SA (0001771910) (Filer)

    3/17/26 12:15:17 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by ADC Therapeutics SA

    424B3 - ADC Therapeutics SA (0001771910) (Filer)

    3/16/26 5:02:29 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by ADC Therapeutics SA

    S-3 - ADC Therapeutics SA (0001771910) (Filer)

    3/10/26 5:09:40 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    $BNTX
    $LAZR
    $MPW
    Financials

    Live finance-specific insights

    View All

    ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

    LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026Recent amendment to HealthCare Royalty financing agreement increases strategic flexibilityFourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028Company to host conference call today at 8:30 a.m. EDTLAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results f

    3/10/26 7:30:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

    BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb Full year 2025 revenues of €2.9 billion2, net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.314) (adjusted3 diluted loss per share of €0.48 ($0.554)) Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5Expect 202

    3/10/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026

    LAUSANNE, Switzerland, March 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, March 10, 2026, at 8:30 a.m. EDT to report financial results for the fourth quarter and full year ended December 31, 2025, and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you

    3/3/26 7:15:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    $BNTX
    $LAZR
    $MPW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

    SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    11/14/24 9:00:57 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Victorias Secret & Co.

    SC 13G/A - Victoria's Secret & Co. (0001856437) (Subject)

    11/14/24 4:11:11 PM ET
    $VSCO
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ADCT
    $BNTX
    $LAZR
    $MPW
    Leadership Updates

    Live Leadership Updates

    View All

    Tim Johnson Nominated to Join Amaero Board

    MCDONALD, Tenn., March 10, 2026 (GLOBE NEWSWIRE) -- Amaero Ltd (ASX:3DA) (OTC:AMROF) ("Amaero" or the "Company"), a leading U.S. domestic producer of high-value refractory and titanium alloy powders for additive and advanced manufacturing of components utilized by the defense, space, and aviation industries, is pleased to announce that Tim "TJ" Johnson has been nominated to join Amaero's Board as a Non-Executive Director, subject to satisfying the requisite regulatory requirements. Upon joining the Board as a Non-Executive Director, it is anticipated that he will assume the responsibilities of Chairman of the Audit and Risk Committee. Mr. Johnson is an experienced corporate board member

    3/10/26 8:00:00 AM ET
    $DLTR
    $DRVN
    $EAT
    Department/Specialty Retail Stores
    Consumer Discretionary
    Automotive Aftermarket
    Restaurants

    Victoria's Secret & Co. Reports 2025 Fourth Quarter and Full Year Results

    Fourth Quarter and Full Year Results Exceeded Top- and Bottom-line GuidanceComparable Sales Increased 8% in the Fourth Quarter and 5% for the Full YearFourth Quarter and Full Year Adjusted Operating Income Significantly Exceeded ExpectationsInitiates First Quarter and Fiscal 2026 Guidance REYNOLDSBURG, Ohio, March 05, 2026 (GLOBE NEWSWIRE) -- Victoria's Secret & Co. ("VS&Co" or the "Company") (NYSE:VSCO) today reported financial results for the fourth quarter and fiscal year ended January 31, 2026. Hillary Super, VS&Co Chief Executive Officer, said, "We delivered an exceptional fourth quarter and a standout year, exceeding top- and bottom-line guidance with broad based outperformance acr

    3/5/26 7:00:00 AM ET
    $VSCO
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

    Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer ("CPO") effective March 1, 2026. The appointment is in line with BioNTech's strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jimenez will be responsible for shaping and leading BioNTech's people strategy and its execution in alignment with the Company's priorities and business goals. She will focus on attractin

    1/28/26 8:00:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care